Clinical trials
Recurrent Cancer clinical trials
Below are recruiting recurrent cancer clinical trials, each written for real people, not researchers. We’re tracking 680 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07234981RecruitingPhase 2
Using PSMA-PET to guide less intense radiation for returning prostate cancer
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
Omaha, NebraskaAges 30 years+ - NCT07056205Enrolling by invitation
Comparing hormone markers in first and returning breast cancer
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
SohagAges Any age - NCT05933733Recruiting
Salvage treatment for breast cancer that returned locally
This trial looks at how well “salvage” treatments work for breast cancer that has come back only in the local area (like the chest wall or nearby lymph nodes), without spreading to distant organs. It also tracks side effects to better understand the risks and benefits for patients who need additional treatment.
SeoulAges 18–100 - NCT06840002RecruitingPhase 1/Phase 2
Targeted drug plus chemotherapy for recurrent ovarian cancer
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06813898RecruitingEarly Phase 1
A New Scan for Early Prostate Cancer Recurrence
This study tests a new scanning method (rhPSMA-7.3 PET/CT) to detect prostate cancer recurrence when PSA is slightly high. If your PSA is low but rising, and standard scans haven't found cancer, this scan might help locate it.
Chicago, IllinoisAges Any age - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT04415853RecruitingPhase 3
Larotinib for advanced esophageal cancer with high EGFR
This phase 3 trial tests larotinib, a targeted cancer medicine, for people with advanced or recurrent esophageal cancer that has high EGFR. It aims to see if it works better than standard treatment approaches after the cancer has progressed twice.
Beijing, Beijing MunicipalityAges 18–80 - NCT05186493Recruiting
Robot-assisted surgery for advanced pelvic cancer
This study looks at a robot-assisted, minimally invasive surgery approach for people with advanced pelvic cancer that needs a pelvic exenteration operation. It may help some patients have surgery with smaller cuts, depending on whether they are good candidates for this type of procedure.
OsloAges 18 years+ - NCT06680791Recruiting
Endometrial cancer study on recurrence prevention and lifestyle
This study looks at how your cancer type and daily habits might help prevent endometrial cancer from coming back. It only requires that you've had endometrial cancer and a hysterectomy.
PragueAges Any age - NCT07395505Enrolling by invitation
Surgery for advanced rectal or anal cancer
This trial studies the results of a major surgery called pelvic exenteration for patients with advanced rectal or anal cancer that has spread to nearby tissues or bones but not to distant organs. The goal is to see how well the surgery works and how patients recover afterward.
TaoyuanAges 20 years+ - NCT05169112RecruitingPhase 3
Hormone therapy to prevent prostate cancer coming back
This trial studies whether hormone therapy (also called ADT) after prostate surgery lowers the chance that prostate cancer will return. It targets people with very low PSA after surgery but with a higher predicted risk of recurrence.
Halifax, Nova ScotiaAges 18 years+ - NCT06976944RecruitingPhase 2
Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Nagoya, Aichi-kenAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT07144826RecruitingEarly Phase 1
Probiotic for Gut and Vaginal Health in Ovarian Cancer Chemotherapy
This trial tests whether taking a probiotic supplement can help balance the bacteria in your gut and vagina while you undergo chemotherapy for advanced ovarian cancer. It aims to see if this could improve your treatment experience or outcomes.
Columbus, OhioAges 18 years+ - NCT05255471RecruitingPhase 3
Olaparib after surgery for recurrent ovarian cancer
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
NaplesAges 18 years+ - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT07190443RecruitingPhase 3
Abemaciclib after local recurrence in HR+ HER2- breast cancer
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Koto-ku, TokyoAges 18 years+ - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT06769828Recruiting
Ga-68-FAPI-46 PET scan for colorectal cancer recurrence with rising CEA
This trial tests a new type of PET scan called Ga-68-FAPI-46 to help find if your colorectal cancer has returned when your CEA levels are rising. It might offer a more accurate way to detect recurrence early.
Taipei, BeitouAges 20–100 - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT06201078RecruitingPhase 2
Second radiation for prostate cancer that returns locally
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
GliwiceAges 18–80 - NCT06704659Recruiting
Repeated radiation for recurrent breast cancer
This study tests giving a second round of radiation therapy to women whose breast cancer has come back in the same breast, at least 3 years after their first radiation. It may be an option for women 55 and older who have a small, local recurrence that can be removed with surgery.
HelsinkiAges 55 years+
Hear when a new Recurrent Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent cancer?
- Yes. Clin2 currently lists 680 recruiting recurrent cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.